InMed Pharmaceuticals (INM) Depreciation & Amortization (CF) (2019 - 2026)

InMed Pharmaceuticals has reported Depreciation & Amortization (CF) for 8 years, with the latest figure at $50509.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 3.43% year-over-year to $50509.0 in Q1 2026; TTM through Mar 2026 was $209664.0, a 2.42% decrease from a year earlier, with the FY2025 full-year figure at $212839.0, down 3.08% from the prior year.
• Depreciation & Amortization (CF) was $50509.0 for Q1 2026 at InMed Pharmaceuticals, down from $53201.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $55231.0 in Q4 2023, with the low at $49048.0 in Q3 2022.
• Average Depreciation & Amortization (CF) over 5 years is $52878.1, with a median of $53203.0 recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) surged 94.52% in 2022, then dropped 4.97% in 2023.
• Over 5 years, Depreciation & Amortization (CF) stood at $49049.0 in 2022, then rose by 12.6% to $55231.0 in 2023, then slipped by 3.67% to $53203.0 in 2024, then fell by 0.0% to $53201.0 in 2025, then retreated by 5.06% to $50509.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $50509.0 (Q1 2026), $53201.0 (Q4 2025), and $53202.0 (Q3 2025), per Business Quant data.